2019 Q1 Form 10-Q Financial Statement
#000156459019016543 Filed on May 07, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $9.000K | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $4.450M | $2.420M |
| YoY Change | 83.88% | 24.74% |
| % of Gross Profit | ||
| Research & Development | $12.43M | $10.44M |
| YoY Change | 19.15% | 57.55% |
| % of Gross Profit | ||
| Depreciation & Amortization | $216.0K | $95.00K |
| YoY Change | 127.37% | 46.15% |
| % of Gross Profit | ||
| Operating Expenses | $16.88M | $12.86M |
| YoY Change | 31.31% | 50.11% |
| Operating Profit | -$16.87M | -$12.85M |
| YoY Change | 31.33% | 50.19% |
| Interest Expense | -$210.0K | -$30.00K |
| YoY Change | 600.0% | -94.23% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$213.0K | -$34.00K |
| YoY Change | 526.47% | -93.46% |
| Pretax Income | -$17.08M | -$12.88M |
| YoY Change | 32.61% | 42.01% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$1.185M | -$12.88M |
| YoY Change | -90.8% | 41.96% |
| Net Earnings / Revenue | -13166.67% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$11.09M | -$9.684M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 23.02M | 19.91M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $80.12M | $74.00M |
| YoY Change | 8.28% | 156.18% |
| Cash & Equivalents | $31.00M | $17.79M |
| Short-Term Investments | $49.13M | $56.21M |
| Other Short-Term Assets | $1.600M | $3.100M |
| YoY Change | -48.39% | 158.33% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $81.69M | $77.10M |
| YoY Change | 5.95% | 156.67% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.813M | $1.400M |
| YoY Change | 172.36% | 90.74% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.300M | $200.0K |
| YoY Change | 550.0% | -94.32% |
| Total Long-Term Assets | $13.01M | $1.600M |
| YoY Change | 713.19% | -62.41% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $81.69M | $77.10M |
| Total Long-Term Assets | $13.01M | $1.600M |
| Total Assets | $94.70M | $78.70M |
| YoY Change | 20.33% | 129.49% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.800M | $1.800M |
| YoY Change | 55.56% | 90.07% |
| Accrued Expenses | $11.20M | $7.900M |
| YoY Change | 41.77% | 0.56% |
| Deferred Revenue | $36.00K | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $2.200M | $7.200M |
| YoY Change | -69.44% | 0.0% |
| Total Short-Term Liabilities | $16.20M | $16.90M |
| YoY Change | -4.14% | 5.13% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $24.10M | $2.000M |
| YoY Change | 1105.0% | -76.7% |
| Other Long-Term Liabilities | $9.600M | $200.0K |
| YoY Change | 4700.0% | 100.0% |
| Total Long-Term Liabilities | $33.70M | $2.200M |
| YoY Change | 1431.82% | -74.37% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $16.20M | $16.90M |
| Total Long-Term Liabilities | $33.70M | $2.200M |
| Total Liabilities | $49.90M | $19.06M |
| YoY Change | 161.79% | -46.76% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$233.0M | -$179.8M |
| YoY Change | 29.56% | 31.18% |
| Common Stock | $277.8M | $239.6M |
| YoY Change | 15.95% | 5669.2% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$1.919M | $59.68M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $94.73M | $78.74M |
| YoY Change | 20.31% | 129.6% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$1.185M | -$12.88M |
| YoY Change | -90.8% | 41.96% |
| Depreciation, Depletion And Amortization | $216.0K | $95.00K |
| YoY Change | 127.37% | 46.15% |
| Cash From Operating Activities | -$17.68M | -$12.71M |
| YoY Change | 39.14% | 67.87% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $133.0K | $220.0K |
| YoY Change | -39.55% | 315.09% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $6.230M | -$3.440M |
| YoY Change | -281.1% | -190.05% |
| Cash From Investing Activities | $6.097M | -$3.661M |
| YoY Change | -266.54% | -197.11% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $248.0K | $29.00K |
| YoY Change | 755.17% | -29.27% |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 1.770M | -1.771M |
| YoY Change | -199.94% | -133.8% |
| NET CHANGE | ||
| Cash From Operating Activities | -17.68M | -12.71M |
| Cash From Investing Activities | 6.097M | -3.661M |
| Cash From Financing Activities | 1.770M | -1.771M |
| Net Change In Cash | -9.815M | -18.14M |
| YoY Change | -45.89% | -1359.72% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$17.68M | -$12.71M |
| Capital Expenditures | $133.0K | $220.0K |
| Free Cash Flow | -$17.82M | -$12.93M |
| YoY Change | 37.8% | 69.59% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.65 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19905871 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2000000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71082000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
29000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1521000 | |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
94728000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
44854000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58145000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
103081000 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3813000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
7901000 | |
| CY2018Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
26201000 | |
| CY2019Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2019Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2019Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30998000 | |
| CY2019Q1 | us-gaap |
Marketable Securities
MarketableSecurities
|
49125000 | |
| CY2019Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1566000 | |
| CY2019Q1 | us-gaap |
Assets Current
AssetsCurrent
|
81689000 | |
| CY2019Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
27000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16534000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
274029000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-215884000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-23000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
9558000 | |
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
277781000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-232968000 | |
| CY2019Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
18000 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23210862 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23000151 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23210862 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23000151 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9000 | |
| CY2019Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12434000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10436000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4446000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2419000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
16880000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
12855000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16871000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12846000 | |
| CY2019Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
541000 | |
| CY2018Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
315000 | |
| CY2019Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
754000 | |
| CY2018Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
349000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-213000 | |
| CY2018Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-34000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17084000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12880000 | |
| CY2019Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
41000 | |
| CY2018Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-74000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17043000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-12954000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.74 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23040951 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
248000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1504000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
41000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-74000 | |
| CY2019Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
142000 | |
| CY2018Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
147000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17682000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
6097000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3661000 | |
| CY2018Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
49107000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
55296000 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
18000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
26000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
41000 | |
| CY2018Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
46000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-9000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-9000 | |
| CY2019Q1 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
251000 | |
| CY2018Q1 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
159000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12708000 | |
| CY2018Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
1800000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
248000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
29000 | |
| CY2019Q1 | toca |
Proceeds From Issuance Of Common Stock Under Atm Facility Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockUnderATMFacilityNetOfIssuanceCost
|
1522000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1770000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1771000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-9815000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-18140000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
35933000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
17793000 | |
| CY2019Q1 | us-gaap |
Interest Paid
InterestPaid
|
606000 | |
| CY2018Q1 | us-gaap |
Interest Paid
InterestPaid
|
214000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
26000 | |
| CY2018Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
45000 | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Significant estimates in the Company’s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p> | |
| CY2018Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
205000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
49125000 | |
| CY2019Q1 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
|
0 | |
| CY2019Q1 | toca |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
3692000 | |
| CY2018Q4 | toca |
Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
|
4535000 | |
| CY2019Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1690000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2840000 | |
| CY2019Q1 | toca |
Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
|
2569000 | |
| CY2018Q4 | toca |
Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
|
3411000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
796000 | |
| CY2019Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
246000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
474000 | |
| CY2019Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
211000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1956000 | |
| CY2019Q1 | toca |
Working Capital
WorkingCapital
|
65500000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
80100 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3428585 | |
| CY2019Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1629000 | |
| CY2019Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
5507020 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2000000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1521000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
The Company leases its office and laboratory space located in San Diego, California, for its corporate headquarters and research facility under an operating lease agreement (the Lease). The Lease commenced in March 2018. | |
| CY2019Q1 | toca |
Lessee Operating Lease Commenced Period
LesseeOperatingLeaseCommencedPeriod
|
2018-03 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P8Y | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
the Company has one option to extend the Lease for a period of five additional years. | |
| CY2019Q1 | toca |
Lessee Operating Lease Additional Term Of Contract
LesseeOperatingLeaseAdditionalTermOfContract
|
P5Y | |
| CY2019Q1 | toca |
Lessee Operating Lease Tenant Improvement Allowance
LesseeOperatingLeaseTenantImprovementAllowance
|
1200000 | |
| CY2019Q1 | toca |
Lessee Operating Lease Term Of Terminate
LesseeOperatingLeaseTermOfTerminate
|
P9M | |
| CY2019Q1 | toca |
Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
|
0.109 |
